Study to Evaluate the Inflammatory Cells Activity in Patients With Persistent Asthma Treated With Montelukast
Information source: Merck
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: montelukast sodium (Drug); Comparator: placebo comparator (Drug)
Phase: Phase 3
Sponsored by: Merck
Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Verify if the quantitative parameters of the eosinophils activation and phagocyte system
function show a predictive value for clinical response and prognostic in patients with
persistent asthma treated with montelukast
Official title: Prospective, Randomized, Double-Blind, Study to Evaluate the Eosinophils Activation Parameters and Phagocyte Function in Patients With Persistent Asthma Treated With Montelukast
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Verify if the quantitative parameters of the eosinophils activation and phagocyte system function show a predictive value for clinical response and prognostic.
Minimum age: 2 Years.
Maximum age: 18 Years.
- Patients Between 2-18 Years With Persistent Asthma
- Patients > 18 Years Old And < 2 Years Old
Locations and Contacts
Merck Sharp & Dohme Farmaceutica Ltda., Sao Paulo, SP 04717-004, Brazil; Recruiting
Jose Octavio P. Costa Filo, Phone: 55-11-5189-7942
MedWatch - FDA maintained medical product safety Information
PhRMA Clinical Study Results Database - web-based repository for clinical study results
Merck: Patient & Caregiver U.S. Product Web Site
Starting date: October 2008
Ending date: April 2009
Last updated: January 8, 2009